Holden S E, Currie C J
Cochrane Institute of Public Health, School of Medicine, Cardiff University, Cardiff, UK.
Diabetes Obes Metab. 2014 Oct;16(10):885-90. doi: 10.1111/dom.12280. Epub 2014 Mar 14.
Current clinical guidelines in the USA and the UK recommend first-line glucose-lowering treatment with metformin monotherapy for glucose control in type 2 diabetes, where not contraindicated. Consequently, the proportion of people treated with sulphonylureas is decreasing. The purpose of this commentary is to discuss the risks and benefits associated with sulphonylurea monotherapy versus metformin monotherapy and the evidence that, in comparison with metformin, sulphonylureas cause increased harm to people with type 2 diabetes.
美国和英国目前的临床指南建议，在无禁忌证的情况下，2型糖尿病患者的一线降糖治疗采用二甲双胍单药治疗以控制血糖。因此，接受磺脲类药物治疗的患者比例正在下降。本评论的目的是讨论磺脲类药物单药治疗与二甲双胍单药治疗相关的风险和益处，以及与二甲双胍相比，磺脲类药物对2型糖尿病患者造成更大伤害的证据。
